Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaborati ...

Q2 2025 Management View Kabir Kumar Nath, CEO, announced the appointment of Justin Gover, former CEO of GW Pharmaceuticals, to the Board of Directors, highlighting his experience with "Epidiolex, the ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20251104736485/en/ ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey ...

LONDON & NEW YORK, November 20, 2025--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in ...

Investing.com - Oppenheimer has upgraded Compass Pathways (NASDAQ:CMPS) from Perform to Outperform, setting a price target of $15.00 based on the potential of its psilocybin therapy for ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in ...

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — ...